YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer
Canadian Respiratory Journal · 2023
DOI: 10.1155/2023/4689004 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Respiratory Journal, 2023. Verfasst von Ling-Chen Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Institute, Xinqiao Hospital, Army Medical University, Chongqing 400037, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Adenocarcinoma of Lung. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Innovation Special Project of Chongqing Social Undertakings and Livelihood Security, Key Special Projects for Technological Innovation and Application Development of Chongqing.
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs) have become a standard care in non-small-cell lung cancer (NSCLC). However, its application to epidermal growth factor receptor (EGFR)-mutant NSCLC patients is confronted with drug resistance. This study aimed to clarify the potential role of Yes1-associated transcriptional regulator (YAP1) in ICIs treatment for EGFR-mutant NSCLC population.
Methods
All the clinical data of NSCLC were downloaded from Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) for GSE11969 and GSE72094. Based on YAP1 expression, all the NSCLC patients including the EGFR-mutant and EGFR-wildtype (WT) patients were divided into two groups, YAP1_High and YAP1_Low. Using cBioPortal, genetic alterations were analyzed for identification of immunogenicity in EGFR-mutant NSCLC. MR analysis was used to analyze the hub gene of EGFR. The infiltration of immune cells and the expression of the identified tumor-associated antigens were identified with TIMER. By graph learning-based dimensionality reduction analysis, the immune landscape was visualized. Moreover, survival analysis was performed to verify the predictive value of YAP1 in ICIs treatment for EGFR-mutant NSCLC population using Ren’s research data (NCT03513666).
Results
YAP1 was a poor prognostic factor of EGFR-mutant NSCLC population rather than lung adenocarcinoma (LUAD) patients. MR analysis revealed that the EGFR gene regulated YAP1 expression. YAP1 was identified as a hub gene closely associated with immunosuppressive microenvironment and poor prognosis in EGFR-mutant NSCLC population in TCGA LUAD. Tumors with YAP1_High showed an immune-“cold” and immunosuppressive phenotype, whereas those with YAP1_Low demonstrated an immune-“hot” and immunoactive phenotype. More importantly, it was verified that YAP1_High subpopulation had a significantly shorter progression-free survival (PFS) and overall survival (OS) after ICIs treatment in EGFR-mutant NSCLC patients in the clinical trial.
Conclusions
YAP1 mediates immunosuppressive microenvironment and poor prognosis in EGFR-mutant NSCLC population. YAP1 is a novel negative biomarker of ICIs treatment in EGFR-mutant NSCLC population. Clinical Trials. This trial is registered with NCT03513666.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Cancer Institute, Xinqiao Hospital, Army Medical University, Chongqing 400037, China.
- Medical English Department, College of Basic Medicine, Army Medical University, Chongqing 400038, China.
- Department of Medical Oncology, Cancer Hospital, Chongqing University, Chongqing 400030, China.
ORCID-Profile: Ling-Chen Li, Xie-Wan Chen, Ling Fang, Chun-Li Jian, Yong-Xin Yu, Xing-Yun Liao, Jian-Guo Sun
Förderung
- National Natural Science Foundation of China
- Science and Technology Innovation Special Project of Chongqing Social Undertakings and Livelihood Security
- Key Special Projects for Technological Innovation and Application Development of Chongqing
- Army Medical University
Zitieren
APA
Li, L. C., Chen, X. W., Fang, L., Jian, C. L., Yu, Y. X., Liao, X. Y., & Sun, J. G. (2023). YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer. Canadian Respiratory Journal. https://doi.org/10.1155/2023/4689004
Vancouver
Li LC, Chen XW, Fang L, Jian CL, Yu YX, Liao XY, et al. YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer. Canadian Respiratory Journal. 2023. doi:10.1155/2023/4689004
BibTeX
@article{Li2023,
author = {Li, Ling-Chen and Chen, Xie-Wan and Fang, Ling and Jian, Chun-Li and Yu, Yong-Xin and Liao, Xing-Yun and Sun, Jian-Guo},
title = {YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer},
journal = {Canadian Respiratory Journal},
year = {2023},
doi = {10.1155/2023/4689004}
}
EUVIMED